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In Vitro Analysis of Nanoparticulate Hydroxyapatite/Chitosan
Composites as Potential Drug Delivery Platforms for the
Sustained Release of Antibiotics in the Treatment of
Osteomyelitis
VUK USKOKOVIĆ and TEJAL A. DESAI
Therapeutic Micro and Nanotechnology Laboratory, Department of Bioengineering and
Therapeutic Sciences, University of California, San Francisco, California 94158-2330
Abstract
Nanoparticulate composites of hydroxyapatite (HAp) and chitosan were synthesized by
ultrasound-assisted sequential precipitation and characterized for their microstructure at the atomic
scale, surface charge, drug release properties, and combined antibacterial and osteogenic response.
Crystallinity of HAp nanoparticles was reduced because of the interference of the surface layers of
chitosan with the dissolution/reprecipitation-mediated recrystallization mechanism that conditions
the transition from the as-precipitated amorphous calcium phosphate phase to the most
thermodynamically stable one—HAp. Embedment of 5–10 nm sized, narrowly dispersed HAp
nanoparticles within the polymeric matrix mitigated the burst release of the small molecule model
drug, fluorescein, bound to HAp by physisorption, and promoted sustained-release kinetics
throughout the 3 weeks of release time. The addition of chitosan to the particulate drug carrier
formulation, however, reduced the antibacterial efficacy against S aureus. Excellent cell spreading
and proliferation of osteoblastic MC3T3-E1 cells evidenced on microscopic conglomerates of
HAp nanoparticles in vitro also markedly diminished on HAp/chitosan composites. Mitochondrial
dehydrogenase activity exhibited normal values only for HAp/chitosan particle concentrations of
up to 2 mg/cm2 and significantly dropped, by about 50%, at higher particle concentrations (4 and
8 mg/cm2). The gene expression of osteocalcin, a mineralization inductor, and the transcription
factor Runx2 was downregulated in cells incubated in the presence of 3 mg/cm2 HAp/chitosan
composite particles, whereas the expression of osteopontin, a potent mineralization inhibitor, was
upregulated, further demonstrating the partially unfavorable osteoblastic cell response to the given
particles. The peak in the expression of osteogenic markers paralleling the osteoblastic
differentiation was also delayed most for the cell population incubated with HAp/chitosan
particles. Overall, the positive effect of chitosan coating on the drug elution profile of HAp
nanoparticles as carriers for the controlled delivery of antibiotics in the treatment of osteomyelitis
was compensated for by the lower bacteriostatic efficiency and the comparatively unviable cell
response to the composite material, especially at higher dosages.
© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association
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INTRODUCTION
Osteomyelitis, infectious inflammation of bone,1 targets a considerable number of patients,
particularly among the three most critical populations: children, elders, and inhabitants of
Third World countries. The mainstay therapy for this comparatively rare disease with the
incidence of approximately 1%–2% in the USA2 has consisted of: (1) intravenous
administration of antibiotics for 2–6 weeks depending on the severity of the infection,
frequently followed by a 6-month course of oral antibiotics in the case of chronic
osteomyelitis, and (2) surgical debridement of the portion of bone that has undergone
necrosis because of the restriction of blood flow by the formed abscesses.3,4 The immediate
downsides of this traditional therapy include: (1) the side effects and cost-ineffectiveness of
systemic administration of antibiotics; (2) low concentration of the therapeutic agent around
the site of infection consequential to obstructed vasculature, prone to induce the resistance
of the pathogen to the antibiotic therapy; and (c) irretrievable bone loss that often demands
insertion of implants or prostheses as lasting bone substitutes.
It is believed that although local and sustained release of the drug could overcome the need
for prolonged antibiotic therapies, induction of osteogenesis by the carrier itself could
accelerate the bone healing process and minimize the extent of the surgical removal of
affected bone, along with skeletal deformations and unaesthetic physical disfigurement
entailed by it. Moreover, as the surgical implantation of orthopedic substitutes presents a
major source of infection in the clinical setting, with the postoperational infection rates
ranging from 1% to 3% for primary joint replacement5 to 15% for primary knee surgeries6
to up to 50% for open fracture revisions of tibia,7 there is a great demand to develop
prophylactic materials as either intrinsic components of regular implants or space-filling
adjuvants that would facilitate surgical implantation.
Be it prophylactic or remedial, one such drug delivery platform that is simultaneously
antibiotic and osteogenic, if developed, would present a big step forward in finding ways to
improve the conventional approach to prevention and treatment of osteomyelitis. In our
previous studies, we have shown that various stoichiometric forms of calcium phosphate, the
natural constituent of bone, can be used as viable osteoinductive carriers for the delivery of
antibiotics.8 The sustained release of small molecule drugs from calcium phosphate particles
was, however, shown to be contingent on the formation of solid blocks through desiccation.9
For the fabrication of injectable nanoparticulate calcium–phosphate-based gels as drug
carriers, the dispersability of the particles is required, but it comes at the cost of accelerated
release of the drug. In this work, we attempt to overcome this issue and promote more
sustained drug release profiles by coating the drug-containing surface of hydroxyapatite
(HAp) nanoparticles with a marine fiber, chitosan. Because of their ability to (1) act as
plasticizers, (2) protect the drug depots residing on the particle surface from the premature,
USKOKOVIĆ and DESAI Page 2
J Pharm Sci. Author manuscript; available in PMC 2014 June 04.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
burst release, and (3) provide a stable surface that could be chemically functionalized with
various targeting, therapeutic or diagnostic ligands, polymers have been the prime choice of
additives to calcium–phosphate-based composites for bone-filling applications.10
The application of chitosan, a linear polysaccharide and a copolymer of D-glucosamine and
N-acetyl-D-glucosamine, as a potential drug and/or gene delivery carrier has been attracting
attention over the last two decades because of the facts that: (1) chitosan is a naturally
derived polymer, the second most abundant organic material next to cellulose, and easily
extractable from fungal cell walls and crustacean shells, the byproducts of the food
industry11; (2) it has a range of bioactivities ascribed to it, including antimicrobial,
antitumor, anti-inflammatory, and immunity enhancing ones12–15; (3) it is a cationic
polymer able to bind the typically negatively charged biomolecular moieties and transfect
cells,16–18 alongside finding use in water purification industry as an adsorbent of
pollutants19; (4) it is mucoadhesive and capable of increasing the permeability of epithelial
monolayers to various drugs20,21; and (5) it is approved by the US FDA and is available as a
regular fibrous supplement in diet.22 Composites of HAp with chitosan as potential drug
delivery carriers have been synthesized before in different forms: with HAp (1) coated by
the polymer,23,24 and (2) dispersed within chitosan-based polymeric matrices.25–28
Systematic analyses of the controlled release of antibiotics29–33 or other small
molecules34–36 from these composites have been far rarer, especially when coupled to the
analysis of their antibacterial and osteoconductive potencies. One such combined analysis of
drug elution profiles and antibacterial and osteogenic performance of HAp/chitosan
composites has presented the central topic of this study.
MATERIALS AND METHODS
Synthesis and Characterization of HAp Nanopowders and HAp/Chitosan Composite
Nanoparticles Loaded with the Drug
Narrowly dispersed spherical HAp nanoparticles were prepared by adding 200 mL of 0.06
M aqueous solution of NH4H2PO4 containing 12.5 mL 28% NH4OH dropwise (13 mL/min)
to the same volume of 0.1 M aqueous solution of Ca(NO3)2 containing 25 mL 28% NH4OH
at 37°C, vigorously agitated in an ultrasound field using a Q700 (QSonica, New-town, CN)
ultrasonicator, a regular tip, half an inch in diameter (1.3 cm), the amplitude equal to 20 and
pulse on/off time of 2/1 s. After the addition of NH4H2PO4 was complete, the resulting
suspension was cooled down to room temperature and either clindamycin phosphate (Tokyo
Chemical Industry, Tokyo, Japan) in the amount of 100 mg or 0.2 mg fluorescein–Na
(Sigma, Dorset, UK) was added to it, followed by aging for 1 h. To coat thus-obtained HAp
nanoparticles with chitosan [poly(D-glucosamine) deacetylated chitin, Mw = 190–310 kDa;
Sigma], 10 mL of 1 mg/mL chitosan solution in 30 mM HCl was then gradually, over 10
min, added to the sol agitated using the abovementioned ultrasonication conditions. The
precipitate alongside its parent solution was left to age in the atmospheric conditions for 1 h.
After the given time, the precipitate was washed once with deionized (DI) H2O, centrifuged
(5 min at 3500 rpm), and dried in a vacuum oven (Isotemp 280A; p = −20 mmHg) at 60°C.
Prior to the ultrastructural analysis by means of the high-resolution transmission electron
microscopy (HR-TEM), the samples were dispersed in 50:50 (vol) mixture of phosphate-
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buffered saline (PBS) and ethanol, vortexed and a droplet of the resulting dispersion was
smeared on top of a carbon-coated copper grid (Ted Pella, Redding, CA). After 1 min, the
excess liquid was blotted off with filter paper, after which negative staining was performed
by depositing a droplet of 1% aqueous solution of phosphotungstic acid in 30 mM NaOH
(pH 6.7) on top of the grids. Following 1 min incubation in air, the excess liquid was blotted
off and the grids were left to dry in air. The samples were subsequently stored and then
analyzed on a (FEI, Hillsboro, OR) monochromated F20 UT Tecnai HR-TEM under the
electron acceleration voltage of 200 kV.
The phase composition of HAp particles was confirmed on a (Bruker, Billerica, MA) AXS
D4 Endeavour X-ray diffractometer. Interplanar distances (d) with strongest reflections on
X-ray diffractograms were correlated with Miller indices {hkl}, the diffraction angle (θ) and
lattice parameters for the hexagonal lattice of HAp (P63/m space group; a = 0.937 nm and c
= 0.688 nm) using the following equations:
(1)
(2)
The average crystallite diameter (r) was estimated by applying Debye–Scherrer’s equation
on the half-width of (211) diffraction peak of HAp in radians (β1/2), the diffraction angle (θ),
and 1.5418 Å as the wavelength of CuKα as the radiation source (λ):
(3)
The ξ-potential analysis was carried out on a Zetasizer Nano Series (Malvern,
Worceslershire, UK) dynamic light scattering device. The analyzed powders were initially
suspended in 20 mM Tris–HCl solution (pH 7.4). Zeta potential values were measured at
room temperature and at different pH values in the range 4.5–11.5, obtained by adding small
volumes (1–3 μL) of 1 N HCl or NaOH. The volume of each suspension was 700 μL and the
results of each measurement were averaged over 100 runs at acquisition times of
approximately 10 s. The universal dip cell (Malvern) with a removable palladium electrode
and the spacing of 2 mm in disposable glass cuvettes was used for measurements. The
voltage was automatically set to 1.2 V and the Smoluchowski model was applied for the
conversion of the electrophoretic mobility values to ξ-potentials:
(4)
where η is the viscosity coefficient of the medium, ν is the electrophoretic velocity, μ is the
electrophoretic mobility, ε is the dielectric constant of the medium, and E is the gradient of
the electric field applied.
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Drug Release
Drug release experiments were conducted by immersing 1 mg of fluorescein-loaded HAp
and HAp/chitosan powders, separately, in 300 μL of 20 mM Tris–HCl (pH 7.4) in capped
microfuge tubes, and incubating it at room temperature under mild agitation (60 rpm on a
shaker plate) for up to 3 weeks. Every 24–48 h, 100 μL aliquots were sampled out and
analyzed for fluorescence (Packard Fluorocount, λexcitation = 495 nm, λemission = 525 nm)
convertible to the concentration of the released fluorophore, before being replaced with fresh
medium to prevent its saturation. At the end of 3 weeks of release time, the remaining
powders were dissolved in 20 mM HCl. The resulting fluorescence was measured and used
to calculate the overall amount of the drug initially contained by the powders. The drug
released at each time point was then normalized to the overall amount of the released drug.
Each sample was analyzed in triplicates and the fluorescence of each experimental replica
was determined as the average of three independent measurements.
Bacterial Culture
A single colony of Staphylococcus aureus (subspecies aureus Rosenbach; ATCC 25923)
cultured on a blood agar plate over 48 h was stabbed with a pipette tip, which was then
placed in 5 mL of 37 mg/mL brain heart infusion (BHI) broth and kept on an incubator
shaker (Innova 44) overnight at 37°C and 225 rpm. The turbid broth was collected the
following day and 8 mL of it was added to serially diluted samples containing different
concentrations of different clindamycin-loaded powders in 1 mL of 37 mg/mL BHI broth,
for the purpose of determining the minimal inhibitory concentration (MIC) of the antibiotic-
containing powders under the given analytical conditions. The given bacterial concentration
(1:125,000 of 5 mL 37 mg/mL BHI broth inoculated overnight with a single bacterial
colony) was found to be equal to the standard concentration of 105 bacteria per milliliter
after comparing the optical density at λ = 600 nm of a range of serially diluted bacterial
broths with 0.5 M Mc-Farland solution (equivalent to approximately 108 bacteria per
milliliter) prepared by mixing 1% BaCl2 solution and 1% H2SO4 in the volume ratio of
1:200, respectively. The dilution yielding the same absorbance as that of 0.5 M McFarland
solution was diluted 103 times to yield the standard bacterial concentration of 105 bacteria
per milliliter. The series of samples was incubated overnight on the incubator shaker and
visually analyzed the following day for their turbidity and the optical density at λ = 600 nm.
Turbid broths indicated those in which the concentration of the antibiotic released from the
particles was insufficient to prevent the bacterial growth, as opposed to the transparent
broths. A parallel antibacterial test using a modified Kirby–Bauer method was repeated on
sheep blood agar plates (UCSF Cell Culture Facility). A freshly inoculated bacterial broth
was diluted to the concentration of 108 cfu/mL and 200 μL of it was added to the plate and
spread until the surface was fully covered. One milligram of the clindamycin-loaded
particles was then added onto the plate in form of separate islets. The plates were incubated
overnight at 37°C and observed for inhibition of bacterial growth around the nanoparticulate
samples the following day. All the experiments were carried out in quadruplicates and
compared with the negative controls, incubated without any added bacteria and the positive
controls, incubated with bacteria and no antibiotic-loaded particles.
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Cell Culture
Mouse calvarial preosteoblastic cell line, MC3T3-E1 subclone 4, was purchased from
American Tissue Culture Collection (ATCC; Rockville, Maryland) and cultured in Alpha
Minimum Essential Medium (α-MEM; Gibco, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS; Invitrogen, Carls-bad, CA) and no ascorbic acid (AA). The medium
was replaced every 48 h, and the cultures were incubated at 37°C in a humidified
atmosphere containing 5% CO2. Every 7 days, the cells were detached from the surface of
the 75 cm2 cell culture flask (Greiner Bio-One, Monroe, NC) using 0.25 wt % trypsin,
washed, centrifuged (1000 rpm × 3 min), resuspended in 10 mL α-MEM and subcultured in
1:7 volume ratio. Cell passages 17–21 were used for the experiments reported hereby. The
cultures were regularly examined under an optical microscope to monitor growth and
possible contamination.
For the purpose of staining with fluorescent markers, MC3T3-E1 cells were seeded on glass
cover slips placed in 24-well plates and 500 μL of α-MEM supplemented with 10% FBS,
(Invitrogen) and no AA at the density of 6 × 104 cells per well. After 5 days of incubation,
nearly confluent cells were treated with α-MEM containing 50 μg/mL AA as the
mineralization inductor. At the same time, 2–4 mg/cm2 of particles were added to the cells.
After 5 days of incubation in the presence of the drug-containing particles, cells were stained
for f-actin and nucleus. The staining procedure began with washing the cells with PBS (pH
7.4) and fixing them for 15 min in 3.7% paraformaldehyde. The cells were then washed with
PBS 3 × 5 min and then with the blocking solution (PBT = 1% bovine serum albumin, 0.1%
Triton X-100 in PBS) 2 × 5 min. The cells were then blocked and permeabilized in PBT for
1 h, and then incubated in 20 μg/mL 4′,6-diamidino-2-phenylindole dihydrochloride nuclear
counterstain (Invitrogen), 2 μM calcein AM as HAp-particle-staining compound, and 10
μg/mL phalloidin-tetramethylrhodamine (AlexaFluor 555; Invitrogen), all in PBT for 1 h
and then washed with PBS 3 × 5 min. The cover slips containing the fixed and stained cells
were mounted onto glass slides using hard set vectashield and nail polish and were
subsequently imaged on a confocal laser scanning microscope–C1si (UCSF Nikon Imaging
Center, San Francisco, CA) at 20–100× magnification in oil. The final images were obtained
by z-stack volume-rendering 15–20 raw images spaced by 1 μm. All the experiments were
performed in triplicates.
For the purpose of MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide]
in vitro toxicological assay, MC3T3-E1 cells were seeded in 48-well plates at the density of
3 × 104 cells per well and cultured in the abovementioned AA-free medium until confluency
was reached. The AA-free medium was then substituted with the AA-supplemented medium
and, at the same time, different amounts of particles were added to the cells, in the range of
2–8 mg/cm2. At the end of the incubation period, which lasted for 24 and 96 h, 20 μL of 5
mg/mL MTT (M-5655; Sigma) in PBS were added to each well. After 4 h of incubation at
37°C, 220 μL of MTT solubilization solution (M-5655; Sigma) were added to each well.
Following an additional 2 h incubation of softly shaken wells (60 rpm) at room temperature,
100 μL aliquots from each well were analyzed for absorbance at 570 nm on a UV/Vis
spectrophotometric microplate reader (Spectra Max 190; Molecular Devices). All the
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particle types were analyzed in biological sextuplicates and the resulting absorbance values
were normalized to the negative control.
To run a real-time polymerase chain reaction (qPCR) analysis, MC3T3-E1 cells were first
seeded in 96 well plates at the density of 3 × 104 cells per well and cultured in the
abovementioned AA-free medium until confluency was reached. The AA-free medium was
then substituted with the AA-supplemented medium and, at the same time, 1 mg of particles
was added to each well. At the end of the incubation period, which lasted for either 5 or 10
days, cell lysis, reverse transcription (Bio-Rad, Harcules, CA) and qPCR (StepONEPlus;
Applied Biosystems) were performed using the Fast SYBR Green Cells-to-CT kit (Ambion)
in accordance with the manufacturer’s instructions. Each experiment was performed in
triplicates and each experimental replica was analyzed for mRNA expression in triplicates
too (n = 3 × 3). The expressions of one housekeeping gene, β-actin (ACTB), and three
osteogenic markers, osteocalcin (BGLAP), osteopontin (BSP-1), and Runx2 were analyzed.
Table 1 shows the primer pair sequences used.37–39 The real-time PCR results were
analyzed using the ΔΔCt method 40 and all the data were normalized to ACTB expression
levels.
RESULTS AND DISCUSSION
Sizes, morphologies, and phase distribution profiles for HAp nanoparticles alone and in
combination with chitosan can be seen from the transmission electron micrographs
displayed in Figure 1. Although HAp nanoparticles precipitated and dried without the
presence of chitosan formed large-scale aggregates (Figs. 1a–1c), a much greater level of
their dispersability was achieved upon coprecipitation with chitosan (Figs. 1e–1f). Round
HAp particles with relatively sharp edges, quasihexagonal shapes, and narrowly dispersed
sizes, ranging from 2 to 10 nm were detected in both samples. The ultrastructural
characterization by means of HR-TEM resulted in the discernment of individual crystal
planes with structural parameters typical for hexagonal HAp with P63/m space group. The
lattice spacing characteristic of HAp crystal symmetry is visible in Figure 1e, including that
of the hexagonal, (001) plane (d001 = 0.527 nm), and a range of similar interplanar distances
parallel with the c-axis [(001)]—(100), (110), (010), (210)—indicating random orientation
of the crystallites embedded in the chitosan matrix. As expected, the most prominent plane
on the surface of the composite corresponded to (002) plane, perpendicular to the c-axis of
hexagonal crystals, with the characteristic spacing of 0.264 nm (Fig. 1e). As a result of the
application of the ultrasound and thus-achieved good dispersability of precipitated HAp
nanoparticles, the crystalline domains appeared to be well dispersed within the amorphous
polymeric matrix (Fig. 1e). Observed were neither the areas of extensive aggregation of the
ceramic phase nor ceramic-free polymeric regions. The number of HAp particles
encapsulated by the polymer ranged widely from one (~10–20 nm in diameter; inlet of Fig.
1d) to hundreds (~300 nm in diameter; Fig. 1d). The monophasic composition of the
precipitated HAp was confirmed using X-ray diffraction (Fig. 2). The narrow half-width of
the most intensive, (211), reflection indicated comparatively high crystallinity of the ceramic
phase, considering the small, sub-10-nm particle sizes. In fact, Debye–Scherrer’s equation
applied on this peak estimated the average HAp crystallite size at 8.4 nm, indicating an
exceptionally small proportion of amorphous surface layers compared with the crystalline
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bulk of the particles. The thermal energy introduced in the system with the intense
ultrasound is expected to have been crucial in promoting both the excellent crystallinity and
dispersability of the resulting nanoparticles.
Both coating of the as-precipitated HAp particles with chitosan and adsorption of
clindamycin onto them was shown to reduce their crystallinity (Fig. 2). The average
crystallite size estimated using Eq.(3) dropped approximately 30%, down to 5.8 and 5.9 nm
upon coating with chitosan and the adsorption of clindamycin, respectively. Furthermore, as
could be seen from Figure 2a, whereas three distinct diffraction peaks are observed in the
30°–35° region of 2 θ for pure HAp, only a broad peak corresponding to the major, (211),
reflection is seen in the X-ray diffractogram of HAp coated with chitosan (Fig. 2b).
Similarly, in the 45°–55° region of 2θ, pure HAp exhibits four distinct peaks—(222), (130),
(213), and (004)—whereas only weak (213) and (004) reflections, almost merged with the
baseline, are seen in the diffractogram of HAp/chitosan (Fig. 2b). This effect is
consequential to the hindered recrystallization of as-precipitated calcium phosphate particles
with increasing their aging time in the solution. The first phase to precipitate from a solution
supersaturated with respect to calcium phosphate is an amorphous calcium phosphate
phase.41–43 Following the Ostwald–Lussac kinetic principle, which dictates sequential
progression from the least thermodynamically stable phase to the most stable one for which
the supersaturation ratio exceeds 1, this initially formed amorphous phase transforms into
the most stable calcium phosphate phase, HAp, in a process whose time scale varies from
seconds to hours, depending on the solution parameters, including, most importantly, pH,
temperature, polarity of the precipitation medium, and the concentration and identity of
foreign ions. The chitosan molecules bound to the particle surface interfere with the
dissolution/reprecipitation mechanism that conditions this transition44 and reduce the
crystallinity of the particles. The same, although less prominent effect was observed upon
the addition of clindamycin to the as-precipitated HAp particle suspension (Fig. 2c), which
is similarly explained by the rapid adsorption of the antibiotic molecules onto the particle
surface. Two diffraction peaks originating from chitosan were detected in the X-ray
diffractograms of the composites, concordant with the mainly matrix-like nature of the
latter, where sufficiently sized chitosan molecule aggregates existed to allow for the
crystalline order to be established.
Successful coating of HAp particles with chitosan was confirmed using ξ-potential
measurements. As shown in Figure 3, coating of HAp particles with chitosan resulted in the
shift of ξ-potential toward more positive values, typically by 10–15 mV higher than for HAp
at any given pH. The negative charge on the surface of HAp particles at pH greater than 6.7
is an indication of their crystalline nature,45 as the transition from neutral or positive values
to negative ones reflects the amorphous-to-crystalline transition that presumably all calcium
phosphate precipitates pass en route to the final and the most thermodynamically stable,
apatite phase. As a result of cationic glycopolymeric moieties (i.e., finite degree of
protonation of 2-amino groups of D-glucosamine units at physiological pH), the building
blocks of chitosan molecules, chitosan is typified by positive zeta potentials.46–48 Not only
does this surface charge propensity make chitosan capable of opening the tight junctions
between epithelial cells,49 but it also boosts the cell penetration potency of chitosan
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particles,50 in analogy with the role played by polysaccharides residing on the surface of
gram-negative bacteria.51 The deprotonation of the amine groups (pKa 6–6.552; NH3+ →
NH2) on the surface of chitosan particles is, however, responsible for shift to negative ξ-
potential at pH values that exceed the isoelectric point (IEP) of approximately 7.9,
approximately one unit higher than that of pure HAp (6.7). Finally, as seen from Figure 3,
following the 3-week degradation period of HAp/chitosan composite particles in the
solution, the ξ-potential at the physiological pH decreases compared with the value
characteristic of the initial, as-prepared HAp/chitosan particles (3.9 → 0.9 mV), approaching
the negative ξ-potential of pure HAp (−7 mV) and correlating with the degradation of the
polymeric layers and the exposition of the core HAp particles to the solvent.
Correspondingly, the IEP of HAp/chitosan composite decreases from 7.9 to 7.5 following
the polymer degradation and drug release, approaching the IEP of pure HAp: 6.7 (Table 2).
Comparative profiles for the drug release of fluorescein from HAp nanoparticles and HAp/
chitosan composites are presented in Figure 4a. The addition of chitosan mitigated the burst
release of the drug adsorbed on the surface of HAp. Thus, only 15% of the drug was
released from HAp/chitosan in the first 24 h and 50% in the first week of the release time, as
opposed to 60% of the drug being released from pure HAp in the first 24 h and 75% in the
first 48 h. The release from chitosan-stabilized HAp followed a very low kinetic order of
release throughout the entire 3-week release period, equaling zero for the first 4 days of
release and for the release period between days 4 and 21, though with approximately twice
higher release rate in the 0–72 h period than for the 7–21 day time range. Solid fitting of the
kinetics of fluorescein release from HAp/chitosan for the first 72 h and for the period
between 7 and 21 days to a linear regression model is also displayed in Figure 4. Different
release kinetics observed for HAp alone and HAp in combination with chitosan imply
different release mechanisms, defined by the slowest kinetic step: surface desorption in the
former case and diffusion of the drug through the polymeric network and/or degradation of
the polymer in the latter case. Depending on crystallinity, the degrees of cross-linking and
deacetylation, molecular weight (Mw), drug-to-polymer ratio, temperature and particularly
pH of the local environment, the degradation kinetics of chitosan particles, and the release
rate of the encapsulated drug could be find anywhere in the range of hours53 to days54 to
weeks55 to months56 or even longer.57 Similarly to other biopolymers, chitosan degrades in
two stages, the first of which is induced by water uptake, swelling of the polymer and
leaching of low Mw polymeric chains, typically lasting for a week, whereas the second one
involves hydrolytic degradation and on most occasions occurs no sooner than 2 weeks after
the immersion.58 Water uptake is known to result in extensive pore formation and a
consequent increase in the drug release rate.59 This may explain for the fact that although
coating with chitosan managed to suppress the burst release, it did not extend the release
timescale beyond the 3-week window provided by HAp as the drug carrier per se. The
transition from the swelling-induced degradation to the hydrolysis-controlled one
presumably corresponds to the change in the slope of the temporal drug release curve (Fig.
4) around the days 5–7.
The results of testing the particles for their antibacterial activity against S aureus in BHI
broths are shown in Figure 5. Unlike HAp particles loaded with clindamycin using the
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physisorption effect, which showed high effectiveness in suppressing the bacterial growth,
with the MIC of less than 1 mg/mL, stabilization of the given antibiotic-loaded particles
with the surface layer of chitosan markedly diminished their antibacterial activity, as
evidenced by the corresponding increase of their MIC to less than 32 mg/mL. The same tests
carried out on agar plates (Fig. 6) confirmed a gradual decrease in the antibacterial
effectiveness from pure clindamycin to clindamycin-loaded HAp to clindamycin-loaded
HAp/chitosan. Surprisingly, the addition of the same amount of clindamycin and
clindamycin-loaded HAp onto infected agar plates resulted in only approximately twice
smaller inhibition zone around clindamycin-loaded HAp compared with that around pure
clindamycin, indicating excellent antibacterial efficacy of antibiotic-loaded HAp. On the
contrary, the inhibition zone around 5 mg of HAp/chitosan loaded with clindamycin was
smaller than that around 1 mg of clindamycin-loaded HAp. The more sustained release of
the antibiotic from HAp/chitosan led not to expansion, but progressive shrinkage of the
inhibition zone, by approximately 20% between 24 and 72 h. In contrast, the inhibition zone
around clindamycin-loaded HAp increased by 40% in the same period of time. The
significantly higher antibacterial efficacy of clindamycin-loaded HAp particles compared
with clindamycin-loaded HAp/chitosan can be explained by the faster release of the
antibiotic molecules off the particle surface in the absence of the chitosan layer that
stabilizes against the burst release. The tradeoff between a more sustained drug release
profile and a lower antibacterial efficacy can thus be immediately noticed. The released
mass of fluorescein after the 3-week period of release was the same (60 μg of drug per
milligram of carrier) for both HAp and HAp/chitosan, suggesting that antibiotic molecules
were not expelled from the HAp particle surface during the coating process and that the
lower antimicrobial efficacy of antibiotic-loaded HAp/chitosan is mainly because of the
lower initial release of the drug. In addition, (1) the drug release solution, (2) the freshly
inoculated broths, and (3) the broths in which the bacterial growth was inhibited by either of
the powders all had identical pHs (7.4), which discards the possibility of increased
entrapment of the drug because of a greater degree of protonation of chitosan amine groups
at lower pHs that favor bacterial growth. In our former study, we showed a satisfactory
antibacterial effect of clindamycin-carrying HAp nanoparticles coated with poly-lactide-co-
glycolide (PLGA), with the MIC of only 1–2 mg/mL.60 The overnight growth of S aureus in
BHI broths elevated their pH to 8.2, suggesting that alkaline residues of chitosan molecules
might have a less positive effect on suppressing the growth of this particular strain than the
acidic residues of PLGA. Unlike PLGA, whose surface the acidic monomers render
negatively charged under physiological conditions, amino-glycopolymeric chitosan is
positively charged. Adsorption of clindamycin onto HAp particles increased their ξ-potential
in water and at pH 7.4 from −7 to +7.6 mV. Consequently, from the electrostatic attraction
point of view, although the antibiotic molecules would more readily redisperse in the acidic
PLGA layer, they would tend to remain tightly bound to the core particle (HAp) surface,
which would delay their release during the polymer degradation stage. The potential
advantage of the usage of chitosan in terms of its antibacterial performance was, however,
meant to come from its positive surface charge.61–63 Yet, as demonstrated by the agar plate
experiments, chitosan-coated HAp per se did not exhibit any substantial antibacterial effect
against S aureus (Fig. 6d). Another possibility is that the synergy between the antibiotic and
its carrier, in this case HAp/chitosan, accounted for the lower antimicrobial efficacy, which,
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if true, may have been because of the retention of the drug in the surface layers of particles
formed by erosion of the composite, perhaps protected by the aforementioned strong
polymer–ceramic interaction, where it could be picked by the signal from the fluorescent
detector, yet remain unavailable to neutralize the ribosomal RNA of the bacterium.
Confocal images obtained on immunofluorescently stained osteoblastic cells incubated with
HAp and HAp/chitosan particles are shown in Figure 7. The osteoblastic cells were shown
to engage in an intimate contact with HAp particles. Single-plane images demonstrate
extensive cell spreading along the sides of microscopic particle conglomerates of pure HAp,
directly indicating osteoconductivity of the solid phase. Moreover, cytoskeletal
microfilaments adopted healthy, striated morphologies, indicating a satisfactory osteoblastic
response to the given material. Incubation of the cells with HAp/chitosan, however, induced
a less positive osteoblastic response. Cell proliferation appeared to have been somewhat
reduced and no intimate contact such as that achieved at the interface between osteoblastic
cells and pure HAp was visible for HAp/chitosan composites, suggesting their lesser
osteoconductivity compared with that of pure HAp. The elastic modulus of osteoblasts,
estimated at around 20 kPa, is larger than that of fibroblasts (3 kPa) and the
mechanoreciprocity principle dictates that osteoblast proliferation will be higher on stiffer
extracellular matrices and material surfaces.64 This may explain why a more intimate
contact was observed for osteoblastic cells on HAp particles, whose Young’s tensile
modulus was measured by nanoindentation at approximately 120 GPa,65 rather than on less
stiff chitosan (~3 GPa).66 A markedly better contact observed at the HAp/osteoblast
interface than at the one between HAp/chitosan and osteoblasts could also be explained by
the fact that the chemical composition of HAp is practically identical to the mineral phase of
bone, if we were not to account for ionic impurities present in biological apatite. The higher
roughness of the surface of HAp compared with that of chitosan can also be a factor that
contributed to the more intimate contact of osteoblasts with the former phase, as earlier
studies have demonstrated a direct proportionality between the cellular proliferation and the
nanoscale coarseness of the substrates.67,68
These insights were confirmed in the measurements of the cell mitochondrial dehydrogenase
activity, directly indicative of cell viability (Fig. 8a). Namely, incubation with moderate
particle concentrations yielded equally proliferating cells as those comprising the control
sample, but any HAp/chitosan particle concentration higher than 2–4 mg/cm2 resulted in
twofold drops in the mitochondrial activity. This concentration range corresponds to 15–30
mg/mL when normalized to the volume of the cell culture medium, the upper limit of which
was the amount required to suppress the standard concentration of S aureus colony forming
units suspended in broth (105 per milliliter; Fig. 5) from growing. This suggests that the
amount of clindamycin-loaded HAp/chitosan required to suppress the bacterial growth in
vivo would probably have a somewhat unviable effect on osteoblasts that populate the
infected milieu. In contrast, no significant changes in cell viability were detected upon
incubation of osteoblastic cells with the identical amounts of HAp particles. Increased cell
growth inhibition was previously noticed to occur in parallel with the onset of chitosan
degradation.69 Products of degradation of chitosan include glucosamine and various
oligosaccharides able to activate the production of reactive oxygen species and thus inhibit
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the proliferation of tumor cells (the category to which MC3T3-E1 cell line utilized in this
study also belongs), being one of the reasons why chitosan has been widely considered to be
anti-cancerous. By facilitating the nanoparticle uptake by the cell, the positive surface
charge of chitosan may have presented an additional factor that determined the low cell
viability outcome at higher particle concentrations.70 An earlier study has concordantly
demonstrated that chitosan nanoparticles in the same size range as the one used in our work
(10–300 nm) were extensively internalized by the human epithelial Caco-2 cells via clathrin-
mediated endocytosis,71 imposing visible damage to the organelles and enhancing the
paracellular transport of the drug along the way.72 Other studies, particularly on nanosized
particles, could reiterate these findings of the ability of polycationic chitosan to compromise
the cell membrane integrity and promote cytotoxocity, and that on an array of cell types,
from human hepatocytes73 to human intestinal cells74–76 to human gastric cells77 to mouse
melanoma cells.78 As for in vivo tests, although the majority of studies have shown no
harmful effects of the oral consumption of chitosan79 except following long-term intake
(>12 weeks),80 reports claiming that chitosan administered orally and intraperitoneally to
mice induces hyperplasia to foreign body giant cells in the spleen81 and causes other cellular
and physiological abnormalities82,83 could be found in the literature too.
Expression of osteogenic markers typifies the onset of osteogenetic activity of bone cells
and parallels the subsequent mineralization events. Formerly, qPCR studies have
demonstrated a more elevated expression of Col I, Runx2, ALP, and BGLAP in both mouse
C3H10T1/2 and human alveolar bone-marrow-derived mesenchymal stem cells cultured on
HAp/chitosan than in those cultured on chitosan only.84,85 Our previous gene expression
studies have evidenced the ability of nanocrystalline HAp to upregulate these very same
osteogenic markers with respect to the controls grown on standard cell culture plastics.8 The
addition of the nanoparticulate HAp prepared in this study to cultured MC3T3-E1 cells,
however, did not produce statistically significant changes in the expression of two of the
osteogenic markers analyzed: BGLAP and Runx2 (Fig. 8b). BGLAP is a gene encoding for
osteocalcin, a protein that is a potent promoter for nucleation of biominerals, whereas Runx2
is a key transcription factor involved in the differentiation of osteoblasts. Studies have
shown that Runx2 knockout mice completely lose the ability to differentiate mesenchymal
cells to osteoblasts.86 Interestingly, the smaller size of HAp nanoparticles applied in this
study compared with those used earlier8—10–20 versus 20–100 nm—produced a less
favorable effect on the osteogenic activity of MC3T3-E1 cells, despite the fact that it more
closely resembled the dimensions of the apatite platelets in bone: 30 × 20 × 2 nm3.87 This
effect could be explained by a larger uptake of the particles with lower sizes. The particle
size determines the type and efficiency of the transport of nanoparticles across the cell
membrane, which, in turn, codefines the effects that they will exert on the cell.88 Although
the intracellular presence of HAp crystals similar in size and shape to those that present the
outcomes of internal mineralization may slow down the osteogenic activity of the cell, the
binding of the cell to a more stable HAp surface may produce the opposite effect. The
mRNA expression of the more ambiguous osteogenic marker, BSP-1, which encodes for
osteopontin, the protein that acts as a mineralization inhibitor, increased threefold for cells
incubated with HAp and 100-fold for cells incubated with HAp/chitosan. In addition to its
marking mineralization events, BSP-1 is also a negative regulator of proliferation and
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differentiation in MC3T3-E1 cells89 and its dramatic upregulation for cells incubated with
HAp/chitosan is in agreement with their lower viability (Fig. 8a) as well as with a 12-fold
lower expression of the housekeeping gene, ACTB, compared with the control. Moreover, as
shown in Figure 8c, the 10-to-5-day postdifferentiation ratio in the mRNA expression levels
of BGLAP and Runx2 was highest for the cells incubated with HAp/chitosan. Expression of
the two osteogenic markers in MC3T3-E1 cells is known to peak around day 5 after the
addition of differentiation agents. Any interruption of the differentiation of MC3T3-E1
fibroblasts to osteoblast-like cells becomes evident in the delayed peaking of the expression
of osteogenic markers. This all speaks in favor of a more favorable effect of HAp than HAp/
chitosan composites on the bone-forming activity of the osteoblastic cells.
CONCLUSIONS
In this study, an attempt was made to overcome the burst release of small molecules from
well-dispersed HAp nanoparticles by coating their drug-containing surface with a marine
polymer, chitosan. At the same time, the antibacterial effectiveness of the given composite
material and the osteoblastic cell response to it were analyzed. It was demonstrated that the
embedment of 2–10 nm sized, narrowly dispersed HAp nanoparticles within the polymeric
matrix mitigated the burst release of the small molecule model drug, fluorescein, bound to
HAp by physisorption, and promoted zero-order release kinetics throughout most of the 3
weeks of release time, the time scale that falls in the range of the clinical optimality in the
antibiotic treatment of osteomyelitis. The 24-h antibacterial efficacy against S aureus was,
however, markedly lower for clindamycin-phosphate-loaded HAp/chitosan composites
compared with the antibiotic-loaded HAp. Moreover, in sufficient concentrations, chitosan
added to HAp inhibited the proliferation of the osteoblastic MC3T3-E1 cell line and reduced
the excellent cell spreading and intimacy of the material/cell contact observed to take place
upon incubation of the osteoblastic cells with pure HAp. This imperfect response was
corroborated by the detected downregulation of osteocalcin and the transcription factor
Runx2 in cells incubated in the presence of HAp/chitosan composites. The peak in the
expression of osteogenic markers paralleling the osteoblastic differentiation was also
delayed most for the cell population incubated with HAp/chitosan particles. All in all, the
positive effect of chitosan on the antibiotic elution profile of HAp nanoparticles as carriers
for the controlled delivery of antibiotics in the treatment of osteomyelitis has had its
drawbacks in terms of the lower bacteriostatic efficiency and the comparatively unviable
osteoblastic cell response to the composite material, especially at higher dosages. Finally, as
moderate inflammation is essential for normal regeneration,90–92 regardless of the type of
tissue in question, room should be left for the supposition that the relatively unviable
response observed hereby with respect to HAp/chitosan in vitro may be reversed and even
prove to be favorable in fostering bone regeneration in a more complex, in vivo biological
setting.
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Figure 1.
Transmission electron micrographs of pure HAp (a–c) and of HAp/chitosan composites (d–
f) at different magnifications. Outlines of some of the crystalline domains interspersed
within the amorphous polymeric phase are shown in (e).
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Figure 2.
X-ray diffractograms of HAp (a), HAp/chitosan (b), and clindamycin-loaded HAp (c)
powders synthesized in this study, along with {hkl}indices ascribed to the most intensive
reflections of crystalline HAp. Diffraction peaks originating from chitosan are labeled with
“Ch.” The two inlets show magnified 2θ = 30°–35° and 45°–55° regions.
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Figure 3.
Comparative ξ-potential versus pH curves for HAp and HAp/chitosan nanoparticles in 20
mM Tris–HCl, alongside different ξ-potential values at pH 7.4 and IEPs for pure HAp, as-
prepared HAp/chitosan composites, and HAp/chitosan composites following the 3-week
degradation period.
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Figure 4.
Comparative profiles for the cumulative drug release of fluorescein from HAp nanoparticles
(-●-) and HAp/chitosan composites (-▲-), and fitting of the release curve of fluorescein
from HAp/chitosan composites (-▲-) for the first 72 h and for the period between 7 and 21
days to the zero-order kinetics (dashed red lines).
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Figure 5.
Optical transparence at λ = 600 nm (a) and visual appearance (b) of BHI broths inoculated
with S aureus (105 bacteria per milliliter) and different amounts of clindamycin-loaded HAp
(-●-) and HAp/chitosan (-▲-) powders, following 24 h incubation at 37°C. C− dashed line
denotes the absorbance of the negative control, incubated without any added bacteria,
whereas C+ dashed line indicates the absorbance of the positive control, incubated with 105
bacteria per milliliter and no antibiotic-loaded particles.
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Figure 6.
Inhibition zones formed around 1 mg of clindamycin (a), 1 mg of clindamycin-loaded HAp
particles (b), 5 mg of clindamycin-loaded HAp/chitosan particles (c), and 50 mg of HAp/
chitosan particles (d) on sheep blood agar plates seeded with 7 × 103 S aureus bacteria per
mm2 following an overnight incubation. The area around the deposited powders is encircled
with a dashed line.
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Figure 7.
Single-plane confocal optical micrographs of fluorescently stained osteoblastic MC3T3-E1
cells [cytoskeletal f-actin (a–c) or type I collagen (d–f)—red; nucleus—blue] of the control
sample (a and d) and of those incubated with HAp nanoparticles (b and e) and HAp/chitosan
composites (c and f) (both green), following 5 days of incubation. The sizes of the images
are 270 × 270 μm2 (a–d and f) or 450 × 450 μm2 (e).
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Figure 8.
(a) Mitochondrial dehydrogenase activity indicative of cell viability normalized to the
negative control (C−) and determined by the MTT assay after 96 h of incubation with
different HAp/chitosan particle concentrations normalized to surface area of confluent
MC3T3-E1 osteoblastic cells (mg/cm2) and to the volume of the cell culture medium (mg/
mL). Data normalized to the optical density at λ = 570 nm of the negative control are shown
as arithmetic means with error bars representing SD. Samples with significantly (p < 0.05
with respect to the control group) higher cell viability with respect to the control are marked
with a*, whereas those with significantly lower cell viability are marked with a+. (b) The
comparative effect of HAp and HAp/chitosan nanoparticulate powders on the mRNA
expression of osteogenic markers BGLAP and Runx2 in osteoblastic MC3T3-E1 cells.
mRNA expression was detected by quantitative real-time PCR relative to the housekeeping
gene ACTB. Data normalized to expression of ACTB are shown as averages with error bars
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representing SD. Genes significantly (p < 0.05) downregulated with respect to the control
group are marked with *. (c) 10-to-5-day postdifferentiation ratio in the mRNA expression
level detected by quantitative real-time PCR relative to the housekeeping gene ACTB. All
data groups are significantly different (p < 0.05) from the control.
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Table 1
Primer Pair Sequences Used for the qPCR Analysis
Gene Forward 5′–3′Primer Reverse 5′–3′ Primer
ACTB GGCCCAGAGCAAGAGAGGTATCC ACGCACGATTTCCCTCTCAGC
BSP-1 AGGAGGAGGCAGAGCACA CTGGTATGGCACAGGTGATG
BGLAP CTCACAGATGCCAAGCCCA CCAAGGTAGCGCCGGAGTCT
Runx2 AAATGCCTCCGCTGTTATGAA GCTCCGGCCCACAAATCT
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Table 2
The Measured ξ -Potential and IEP Values for Pure HAp and HAp/Chitosan Composites Before and After the
Drug Release Experiment
HAp As-Prepared HAp/Chitosan Postdegradation HAp/Chitosan
ξ -Potential (mV) −7.0 3.9 0.9
IEP 6.7 7.9 7.5
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